Xeris Biopharma (NASDAQ:XERS) Insider Sells $101,002.02 in Stock

Posted by Brenda Bartman on Jun 3rd, 2026

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Free Report) insider Beth Hecht sold 16,667 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $6.06, for a total value of $101,002.02. Following the completion of the transaction, the insider owned 1,176,506 shares in the company, valued at approximately $7,129,626.36. The trade was a 1.40% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Beth Hecht also recently made the following trade(s):

On Friday, May 1st, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The shares were sold at an average price of $6.23, for a total value of $103,835.41.
On Wednesday, April 1st, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The shares were sold at an average price of $5.99, for a total value of $99,835.33.

Xeris Biopharma Stock Performance

Shares of XERS stock traded down $0.07 during mid-day trading on Tuesday, hitting $6.00. 1,406,991 shares of the stock were exchanged, compared to its average volume of 1,838,139. The stock’s fifty day simple moving average is $6.05 and its two-hundred day simple moving average is $6.62. The stock has a market capitalization of $1.04 billion, a price-to-earnings ratio of 100.00 and a beta of 0.85. Xeris Biopharma Holdings, Inc. has a 12-month low of $4.30 and a 12-month high of $10.08. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.50 and a current ratio of 2.12.

Xeris Biopharma (NASDAQ:XERS – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter. The company had revenue of $83.13 million for the quarter, compared to analyst estimates of $79.83 million. Xeris Biopharma had a return on equity of 735.00% and a net margin of 3.81%. On average, analysts forecast that Xeris Biopharma Holdings, Inc. will post 0.12 EPS for the current year.

Institutional Trading of Xeris Biopharma

Several hedge funds have recently made changes to their positions in the company. Cetera Investment Advisers boosted its holdings in shares of Xeris Biopharma by 3.9% in the second quarter. Cetera Investment Advisers now owns 46,332 shares of the company’s stock valued at $216,000 after acquiring an additional 1,735 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Xeris Biopharma by 29.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock worth $63,000 after purchasing an additional 1,820 shares in the last quarter. Royal Bank of Canada raised its holdings in Xeris Biopharma by 6.5% during the fourth quarter. Royal Bank of Canada now owns 38,636 shares of the company’s stock worth $304,000 after purchasing an additional 2,351 shares in the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its position in Xeris Biopharma by 17.7% in the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 16,070 shares of the company’s stock valued at $126,000 after purchasing an additional 2,420 shares during the period. Finally, AlphaCentric Advisors LLC lifted its position in Xeris Biopharma by 5.7% in the first quarter. AlphaCentric Advisors LLC now owns 45,886 shares of the company’s stock valued at $266,000 after purchasing an additional 2,494 shares during the period. Institutional investors and hedge funds own 42.75% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on XERS. Wall Street Zen raised Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 7th. Weiss Ratings downgraded shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Xeris Biopharma in a research note on Monday, March 2nd. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Xeris Biopharma has an average rating of “Hold” and a consensus price target of $10.80.

Check Out Our Latest Analysis on Xeris Biopharma

Xeris Biopharma Company Profile

(Get Free Report)

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.